Praxis Precision Medicines, a clinical-stage genetic neuroscience company, that develops therapies for complex and debilitating brain disorders, announced that it has raised over $100 Million to advance its ion channel modulators for the treatment of neurological disorders.
Praxis portfolio is led by two candidates in phase 2: PRAX-114, a GABAA positive allosteric modulator (PAM) in development for the treatment of major depressive disorder (MDD) and perimenopausal depression, and PRAX-944, a T-type calcium channel blocker, in development for the treatment of essential tremor.
Praxis also plans to advance its earlier stage programs for rare epilepsies and other disorders into clinical development.
Image by Gerd Altmann from Pixabay
